Navigation Links
FutureFuel Corp. Declares Dividend
Date:5/21/2010

ST. LOUIS, May 21 /PRNewswire-FirstCall/ -- On May 21, 2010, FutureFuel Corp. (OTC Bulletin Board: FTFL) filed a Form 8K with the Securities and Exchange Commission declaring a special cash dividend of $0.20 per share.

The board of directors of FutureFuel Corp. (the "Company") has declared a special cash dividend of U.S. $0.20 per share on the Company's common stock, with a record date of June 8, 2010.  For purposes of the record date, those holders of the Company's warrants or options who properly exercise their warrants or options on or before June 8, 2010 will be considered holders of record on such date, whether or not new stock certificates have been issued to such holders by that date.

The dividend is payable June 30, 2010.

FutureFuel Corp. was created in 2005 as a special purpose acquisition vehicle to acquire companies and make a notable impact in the biofuel and fuel industries.  In October 2006, the Company purchased FutureFuel Chemical Company (formerly named "Eastman SE, Inc."), the owner and operator of a chemical and biodiesel manufacturing facility located near Batesville, Arkansas.  Since then, the Company has worked to become a leader in the U.S. biofuel industry, while maintaining the Batesville facility's status as a world-class specialty chemical manufacturer.


'/>"/>
SOURCE FutureFuel Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Michael Troullis Appointed Chief Financial Officer of Quintiles Transnational Corp.
3. ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal Year 2007 on September 12, 2007
4. ThermoGenesis Corp. Reports Fourth Quarter and Fiscal Year 2007 Results
5. MAKO Surgical Corp. Files Registration Statement for Initial Public Offering of Common Stock
6. CellCyte Genetics Corp. Forms Device Division to Develop and Manufacture Stem Cell Cultivation and Replication Products
7. ThermoGenesis Corp. to Present at 2007 Global Life Sciences Conference on Thursday, September 27, 2007
8. Helix BioPharma Corp. announces fiscal 2007 results
9. ThermoGenesis Corp. to Announce First Quarter Fiscal 2008 Results on November 8, 2007
10. Patent on Technology for the Delivery of Stem Cells to the Human Heart Issued to CellCyte Genetics Corp. of Washington
11. Helix BioPharma Corp. announces management changes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... ... July 20, 2017 , ... ... of life, today announced its full advisory board. The board comprises leaders spanning ... of James Crooks, PhD, former VP of Engineering, to Chief Technology Officer. Crooks ...
(Date:7/20/2017)... ... 2017 , ... Corporate Directors Forum is recognizing six San Diego directors for ... Awards. , The awards will be presented Thursday, September 7th, from 6 to 9 ... have made significantly positive contributions in the boardrooms of some of our region’s most ...
(Date:7/18/2017)... ... July 18, 2017 , ... Genedata, a leading provider of ... technology company, has implemented Genedata Biologics ™ to scale-up their bispecific antibody ... and Neurodegenerative Diseases. , The need to systematically evaluate large panels of ...
(Date:7/18/2017)... Fairfield, NJ (PRWEB) , ... July 18, 2017 ... ... in corporate finance technology, DataForm Software ( https://dataformsoftware.com ) announces the migration of ... – to Microsoft Azure. Planet is a team-centric, enterprise work management system that ...
Breaking Biology Technology:
(Date:4/6/2017)... 2017 Forecasts by Product Type ... by End-Use (Transportation & Logistics, Government & Public Sector, ... Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation ... Are you looking for a definitive report on the ... ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/28/2017)... -- The report "Video Surveillance Market by ... Devices), Software (Video Analytics, VMS), and Service (VSaaS, Installation ... 2022", published by MarketsandMarkets, the market was valued at ... reach USD 75.64 Billion by 2022, at a CAGR ... considered for the study is 2016 and the forecast ...
Breaking Biology News(10 mins):